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ABSTRACT 25 
The majority of antibiotics currently used to treat methicillin-resistant 26 
Staphylococus aureus (MRSA) infections, target bacterial cell wall synthesis or protein 27 
synthesis. Only daptomycin has a novel mode of action. Reliance on limited targets for 28 
MRSA chemotherapy, has contributed to antimicrobial resistance.  Two alternative 29 
approaches to the treatment of S. aureus infection, particularly those caused by MRSA, 30 
that have alternative mechanisms of action and that address the challenge of antimicrobial 31 
resistance are cationic host defence peptides and agents that target S. aureus virulence. 32 
Cationic host defence peptides have multiple mechanisms of action and are less likely 33 
than conventional agents to select resistant mutants. They are amenable to modifications 34 
that improve their stability, effectiveness and selectivity. Some cationic defence peptides 35 
such as bactenecin, mucroporin and imcroporin have potent in-vitro bactericidal activity 36 
against MRSA.  Anti-pathogenic agents also have potential to limit the pathogenesis of S. 37 
aureus. These are generally small molecules that inhibit virulence targets in S. aureus 38 
without killing the bacterium and therefore have limited capacity to promote resistance 39 
development.  Potential anti-pathogenic targets include the sortase enzyme system, the 40 
accessory gene regulator (agr) and the carotenoid biosynthetic pathway.  Inhibitors of 41 
these targets have been identified and these may have potential for further development. 42 
 43 
INTRODUCTION 44 
Serious infections caused by Staphylococcus aureus are important globally in the 45 
hospital setting and in the community. These range from minor infections of the skin and 46 
soft tissue, to life-threatening systemic infections, such as bloodstream infections (BSI) 47 
and endocarditis.  Methicillin resistant S. aureus (MRSA) is resistant to most 48 
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conventional -lactam antibiotics due to the carriage of the mecA gene encoding  an 49 
alternative penicillin binding protein, PBP2a for which -lactams have low affinity 50 
(Hartman & Tomasz, 1984, Reynolds & Brown, 1985). The majority of MRSA isolates 51 
are resistant to drugs in the other antibiotic classes including  aminoglycosides and 52 
macrolides (Fluit, et al., 2001).  Our diminishing arsenal of anti-infectives for the 53 
treatment of systemic MRSA infections highlights the need for alternative antimicrobial 54 
agents with superior properties in terms of efficacy, reduction of toxicity and resistance.   55 
Among the agents currently recommended by the Infectious Diseases Society of 56 
America, for the treatment of MRSA infections are vancomycin, clindamycin, 57 
daptomycin, linezolid, trimethoprim, tetracycline and streptogramins (Liu, et al., 2011). 58 
However, increasingly in-vitro resistance to currently-used agents is reported and clinical 59 
failures have occurred (Soriano, et al., 2008, Yoon, et al., 2008, Baltz, 2009, Prabhu, et 60 
al., 2011, Gould, et al., 2012, Ruiz de Gopegui, et al., 2012).  As summarised in Figure 1,  61 
new members of existing anti-bacterial classes in the late phases of clinical trials, with 62 
potential for the treatment of MRSA infections include ceftobiprole, ceftaroline, 63 
dalbavancin, oritavancin (peptidoglycan synthesis inhibitors) and iclaprim (folate 64 
synthesis inhibitor). Ceftobiprole and ceftaroline are novel advanced generation 65 
cephalosporins with a broad activity spectrum and strong affinity for PBP2a with  66 
ceftobiprole showing stability to -lactamases (Zhanel, et al., 2008, Dauner, et al., 2010). 67 
Dalbavancin and oritovancin are semi-synthetic lipoglycopeptides with a heptapeptide 68 
core similar to vancomycin.  In addition to effects on the cell wall, these agents also 69 
disrupt cell membrane integrity through membrane depolarization. They also have longer 70 
half lives allowing for less frequent dosing compared to vancomycin and teicoplanin 71 
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(Zhanel, et al., 2010). The success of these newer agents remains to be assessed 72 
clinically. It is clear that large pharmaceutical companies preferentially appear to favour 73 
the development of new generation classical antibiotic classes, with improved properties.  74 
This may be because, compared to new agents with alternative mechanisms of action, 75 
their safety and efficacy is well established in-vivo and they are amenable to 76 
pharmaceutical preparation.  However, in view of the propensity to develop resistance 77 
associated with conventional current antibiotics and their derivatives, the long-term future 78 
of anti-staphylococcal agents may involve an exploration of agents with alternative and 79 
multiple modes of anti-bacterial activity. Additional properties such as anti-pathogenic or 80 
immunomodulatory activity would also be desirable in novel MRSA drugs.  Such adjunct 81 
properties would be particularly important  for the treatment of community-associated 82 
MRSA (CA-MRSA) which is associated with enhanced virulence that may be toxin-83 
mediated (Voyich, et al., 2005). The investigation of alternative therapeutic agents with 84 
novel mechanisms of action remains largely an activity for academic researchers and 85 
small biotechnology companies.  This type of research has resulted in pre-clinical 86 
developments in the areas of innate immune defence peptides and anti-pathogenic agents 87 
with potential as novel anti-MRSA therapeutics.  For example, cationic peptides offer 88 
multiple and alternative modes of action that may circumvent the problem of 89 
antimicrobial resistance.  Significant improvements, to the chemistry of such peptides, 90 
have increased their attractiveness in terms of pharmacokinetics, toxicity and cost. Anti-91 
pathogenic agents can potentially attenuate the virulence of MRSA and therefore this 92 
therapeutic approach may have significantly less propensity to contribute to antimicrobial 93 
resistance. These novel approaches to the treatment of MRSA infections, though in their 94 
infancy in terms of pharmaceutical development, may provide alternative or 95 
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complementary therapy in the future. Recent developments in these areas and their future 96 
potential as novel anti-infectives are discussed. 97 
 98 
CATIONIC HOST DEFENCE ANTIMICROBIAL PEPTIDES AND THEIR THERAPEUTIC 99 
POTENTIAL 100 
Cationic antimicrobial peptides (CAMPs) are a group of ubiquitous peptides that 101 
are part of the host innate immune system of animals and plants and these molecules have 102 
several properties that make them promising candidates for development as agents for the 103 
treatment of microbial infections including those caused by MRSA. (Hancock & 104 
Patrzykat, 2002, Zhang & Falla, 2006). Native CAMPs are structurally diverse, varying 105 
in size, sequence, content of  helical or -sheet motifs, disulphide bridges and linear 106 
extended structures. Despite their structural diversity CAMPs are all polycationic and 107 
amphipathic,  two features thought to facilitate their antimicrobial mechanism (Dathe, et 108 
al., 1997). The main mechanism of anti-microbial action of HDPs is biophysical rather 109 
than biochemical, where the target is the cytoplasmic membrane structure itself (Figure 110 
2). In Gram-positive and Gram-negative organisms, the antimicrobial activity of CAMPs 111 
is initiated through electrostatic interactions with the anionic phospholipid head-groups of 112 
the cell envelope that may lead to either membrane perturbations as has been shown for 113 
human -defensins (Yeaman, et al., 1998) and magainins (Westerhoff, et al., 1989) or 114 
translocation across the membrane and interaction with various intracellular targets as 115 
occurs for cathelicidins such as LL-37 and bactenecin (Sadler, et al., 2002).  116 
Three host defence peptides have completed, or are in phase III clinical trials; the 117 
magainin 2 analogue pexiganan (MSI-78) for the prevention of diabetic foot ulcers, 118 
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iseganan, from pig protegrin for the treatment of oral mucositis and omiganan for the 119 
prevention of catheter infections and acne. Pexiganan failed to be approved by the FDA 120 
due to non-superiority to approved agents but it remains one of the best studied CAMPs. 121 
Clinical trials involving HDPs have to date, mainly been limited to topical applications 122 
although some, such as the human lactoferrin fragment hLF1-11, for bacteremia and 123 
fungal infection, being developed for systemic applications are in early clinical trials. The 124 
sequences, properties, in-vitro activities and phase of development of some of these 125 
peptides, that may also have potential as S. aureus anti-infectives are outlined in Table 1.  126 
Classic antibiotics target biochemical properties such as folate, peptidoglycan, 127 
nucleic acid and protein synthesis, which are often mediated through enzyme inhibition 128 
or inhibition of binding to intracellular targets.  However, the ability of HDPs to kill 129 
multi-resistant bacteria and to poorly select resistant mutants may be related to the 130 
contribution of additional alternative and multiple pathways to their mechanism of action, 131 
such as depolarisation of the bacterial membrane, pore formation and the induction of 132 
degradative enzymes and disruption of intracellular targets (Hadley & Hancock, 2010). 133 
The potential direct antimicrobial activity of mammalian host defence peptides 134 
can be complemented by a chemotactic activity for phagocytes and memory and effector 135 
T cells (Figure 1). Additionally, they mediate the recruitment of immature dendritic cells, 136 
by direct chemotactic activity or by upregulation of chemokine production in 137 
macrophages, and promote maturation of these dendritic cells directly or indirectly by 138 
inducing production of inflammatory cytokines (IL-1, TNF) (Bowdish, et al., 2005, 139 
Bowdish, et al., 2006, Yeung, et al., 2011). Although these latter activities result in the 140 
local release of pro-inflammatory cytokines, host defence peptides can also reduce the 141 
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systemic production of TNF, IL-1 and IL-6, as has been demonstrated for LL-37 142 
(Mookherjee, et al., 2006). Therefore, HDP modulation of the immune response to 143 
bacteria appears to involve not only enhancement of specific pro-inflammatory responses, 144 
but also suppression of other elements of the pro-inflammatory response, the additive 145 
effects of which contribute to a more controlled inflammatory response after the initial 146 
potent cytokine response (Yeung, et al., 2011). Some of these immunomodulatory 147 
properties alone are sufficient to prevent or clear infection. This was demonstrated by the 148 
efficacy in a mouse model of infection, of an immune defence regulator peptide, IDR1, 149 
which is devoid of direct antimicrobial activity, but which can selectively activate innate 150 
immune responses (Scott, et al., 2007). This peptide has recently entered phase I clinical 151 
safety trials and is intended for use in the prevention of infection in chemotherapy-152 
induced immune-suppression. More recently another immune defence regulator, derived 153 
from the sequence of the bactenecin peptide IDR-1002 has shown enhanced chemokine 154 
induction with a stronger protective effect in an in-vivo model of S. aureus infection 155 
(Nijnik, et al., 2010, Turner-Brannen, et al., 2011). The combination of selective 156 
recruitment of effector cells and suppression of inflammatory cytokines found for these 157 
peptides would result in a balanced anti-infective response with reduced risk of 158 
uncontrolled inflammation. 159 
 160 
CATIONIC HOST DEFENCE PEPTIDES WITH POTENTIAL AS MRSA ANTI-INFECTIVE 161 
AGENTS. 162 
Although approximately 17 cationic peptides are in clinical trials to date (though 163 
not all in the MRSA therapeutic area) (Yeung, et al., 2011), most of these are for topical 164 
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application. While alternative topical agents may be useful for skin and soft tissue 165 
infections, the potential of cationic peptide or HDPs as dual 166 
immunomodulatory/bactericidal agents in S. aureus infections may be realised through 167 
their development as systemic agents. Two of the best studied natural human HDPs are 168 
the cathelicidin, LL-37 and human beta defensin (HBD).  These HDPs are released from 169 
a variety of cells in response to bacterial challenge. However, it has been suggested that 170 
their relatively low in-vivo levels and their inactivation by serum constituents are 171 
inconsistent with an effective direct killing activity in-vivo (Bowdish, et al., 2005).  As 172 
described above, their immunomodulatory activities have been demonstrated and these 173 
may be more important than their direct killing properties (Figure 2). In the area of S. 174 
aureus anti-infectives, both LL-37 and HBDs have served as templates for the 175 
development of derivatives with improved potential for therapeutic application and lower 176 
potential for toxicity than the natural peptides. For example, the combination of HBD 177 
with a specific immune-modulatory peptide (mannose-binding lectin) has recently proved 178 
effective in a MRSA mouse wound infection model (Li, et al., 2010, Li, et al., 2010). LL-179 
37 and its  synthetic derivatives have shown both in-vitro anti-bacterial activity and 180 
inhibition of S. aureus biofilm formation and no significant haemolysis of erythrocytes (a 181 
marker of cell toxicity)  was reported up to 100 g/ml of each derivative (Dean, et al., 182 
2011).  A non-peptide structural mimetic of defensin, with low toxicity,  PMX-30063D is 183 
currently in clinical development for infections involving S. aureus. 184 
   CAMPs from a wide range of non-human sources including pig protegrin, 185 
temporins and syphaxins from frog skin and buforin from toad have been investigated for 186 
their in-vitro activity towards S. aureus including MRSA (Table 1). However, there is 187 
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further merit in the discovery of peptides of non-human and ancient origin because 188 
evolutionary dynamics may have driven the modification of effector molecules in early 189 
organisms while largely conserving the signalling pathways and pattern recognition 190 
systems that respond to infection. Therefore, they have unique structures that may 191 
potently activate specific immune responses that contribute to a more measured 192 
inflammatory response, with limited possibility of cross-resistance to natural HDPs. 193 
Candidate peptides that may be exploited for specific systemic application for MRSA 194 
infections include peptides derived from ancient organisms such as mucroporin and 195 
imcroporin from the venom of the scorpion and the recently described c-arminin1a from 196 
the eumetazoa Hydra. Mucroporin is a 17 amino acid peptide from the venom of Lychas 197 
mucronatus that rapidly kills bacteria by membrane disruption.   The native peptide is 198 
active against MRSA (MIC= 25 g/ml) and other multi-resistant organisms and an 199 
improved MIC of 5 g/ml and a broader spectrum of activity, have been reported for an 200 
amino acid substituted derivative, mucroporin 1 (Dai, et al., 2008).  Imcroporin is an 201 
immune defence peptide from the venom of Isometrus maculates and in-vitro activity has 202 
also been demonstrated against MRSA strains (MIC = 20-50 g/ml). The peptide 203 
demonstrated less than 10 % haemolysis of erythrocytes at the MIC and was comparable 204 
to vancomycin in survival studies on mice infected with S. aureus (Zhao, et al., 2009). A 205 
recombinant 31 amino acid peptide, c-arminin 1a, from the ancient fresh water animal of 206 
the Eumetazoa species,  Hydra magnipapillata, has been recently shown to have potent 207 
anti-MRSA activity in-vitro (0.4 M), does not demonstrate haemolytic activity and its 208 
activity is independent of the salt concentration (Augustin, et al., 2009).  In sequence, this 209 
peptide does not resemble any known protein and it lacks cysteine residues, which would 210 
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facilitate its synthesis and production in large quantities. These properties make c-arminin 211 
an attractive molecule for further exploitation.   The search for ancient cationic peptide 212 
structures with potent activity towards multi-resistant clinically important bacteria such as 213 
MRSA is on-going but has already revealed potential candidates that may serve as lead 214 
compounds.  215 
 216 
CHALLENGES IN DEVELOPING HOST DEFENCE PEPTIDES AS THERAPEUTIC AGENTS. 217 
 218 
The major obstacles to the development of cationic peptides as systemic 219 
therapeutics are concerns about their potential toxicity or immunogenicity and their poor 220 
stability.  In addition concerns about development of peptide resistance and unknown 221 
effects of synthetic HDPs on the natural innate response to infection, have been raised. 222 
Host defence peptides are expensive to produce in commercial quantities and this issue 223 
has also affected their potential for development.  224 
The relative lack of negatively-charged lipids on mammalian cell surfaces and 225 
their weak membrane potential gradient may selectively protect eukaryotes from the 226 
action of cationic peptides. However, some cationic peptides such as LL-37 can 227 
translocate across mammalian cell membranes because their sequence resembles that of 228 
nuclear signalling peptides. Limited data is available on the cytotoxic effects of cationic 229 
peptides on mammalian cells.  LL-37 does not show significant haemolytic activity at 230 
concentrations greater than its antimicrobial activity but in-vitro cytotoxic effects have 231 
been reported that are dependent on the nature and metabolic state of the target cells and 232 
on the evolutionary form of the mature peptide.(Tomasinsig, et al., 2009). Due to their 233 
small size and linear structure the majority of host defence peptides are considered to be 234 
weakly immunogenic but antibodies have been successfully raised against some cationic 235 
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peptides such as defensins, hCAP-18 and lactoferrin (Panyutich, et al., 1991, Shimazaki, 236 
et al., 1996, Sorensen, et al., 1997). In-vivo toxicity is an area that has not been 237 
systematically assessed for cationic host defence peptides and this may be because so few 238 
have proceeded to this level in clinical trials.   239 
It has been suggested that HDPs, if developed as MRSA anti-infectives, would 240 
have low propensity to select resistant mutants compared to classical antibiotics. This is 241 
based on the multiple mechanisms of action of HDPs. However, bacteria and the human 242 
host have co-evolved and S. aureus adaptations have been described for a small number 243 
of host defence peptides. For example reduced susceptibility to defensin and protegrins 244 
has been demonstrated in S. aureus which is mediated by incorporation of positively 245 
charged L-lysine into the cytoplasmic membrane and is catalysed by the product of the 246 
mprF gene (Peschel, et al., 2001, Ernst, et al., 2009).  Interestingly, this membrane 247 
modification also contributes to S. aureus resistance to the CAMP-like agent daptomycin, 248 
which is currently in clinical use for MRSA infections. An investigation of the evolution 249 
of CA-MRSA shows that USA 300 and USA500 strains are more resistant to the innate 250 
immune defence peptides, dermicidin and indolicidin than isolates from the epidemic 251 
clones from which they originated (Li, et al., 2009).  Despite these reported resistances, 252 
the immune-modulatory properties of HDPs, which may arguably be more important than 253 
their direct antimicrobial therapeutic properties, are not influenced by conventional 254 
resistance mechanisms and this is where HDPs may offer a real advantage over 255 
conventional antibiotics.  256 
Natural HDPs may be released either locally at the site of infection or 257 
systemically in response to infection (Yang & Oppenheim, 2004). Some authors have 258 
argued that the augmentation of these triggers or the provision of analogous triggers of 259 
12 
 
host immunity may dampen the natural innate or adaptive responses to infection or may 260 
cause excessive stimulation of inappropriate immune responses. Inappropriate antibody 261 
responses to the administration of self-proteins have been infrequently reported.  The 262 
possibility of unpredictable effects on the natural host immune response highlights the 263 
importance of detailed characterisation of the innate immune response. These 264 
investigations would include characterisation of signalling pathways of pattern 265 
recognition agonists, regulatory elements of innate immunity and selective 266 
immunomodulatory effects of HDPs.  267 
Development of host-defence peptide-based agents for systemic administration 268 
will require considerable efforts to overcome some of the limitations mentioned above.  269 
However, improvements that address some of the limitations of promising candidate 270 
peptides have been reported. Substitution of D-amino acids into the peptide sequence of 271 
LL-37 derivatives was shown to minimise proteolysis and increase antibacterial activity 272 
(Stromstedt, et al., 2009) and the in-vitro cytotoxic effects of LL-37 have been reduced 273 
by truncation of the sequence while antibacterial activity is retained (Nell, et al., 2006). 274 
Modifications that increase overall charge or amphipathicity increase potency, allowing 275 
lower concentrations to be used (Chen, et al., 2005). Pharmacokinetic properties have 276 
improved with the conversion of some host defence peptides, to peptidomimetic or 277 
peptoid forms, use of D- or - amino acids and PEGylation (Hong, et al., 1999, 278 
Hamamoto, et al., 2002, Hancock & Sahl, 2006, Imura, et al., 2007). Some of these host 279 
defence mimics, in addition to their excellent drug-like properties, failed to generate 280 
resistant derivatives of S. aureus in-vitro compared to ciprofloxacin or norfloxacin (Tew, 281 
et al., 2006).  282 
13 
 
Targeted delivery of host defence peptides to the site of infection may further 283 
improve the therapeutic potential of these molecules.  The increased local concentrations 284 
that could be reached with this approach could potentially remove constraints due to 285 
higher relative MICs for some HDPs. Improved delivery has had some success in the area 286 
of host defence peptides as candidates for anticancer therapy, including conjugation to a 287 
‘tumour-homing’ motif, peptide hormone or antibody, bioconversion to an active agent 288 
by tumour-specific enzymes and liposomal technology (Ellerby, et al., 1999, Marks, et 289 
al., 2005, Mader & Hoskin, 2006, Chakrapani, et al., 2008, Jia, et al., 2008, Song, et al., 290 
2009). The identification and assessment of similar targeting approaches for delivery of 291 
defence peptides to sites of infection is in its infancy with antibody conjugation of a 292 
synthetic derivative of a salivary host defence peptide, histatin serving as an example. 293 
While pro-peptide inactivity in this case has not been clearly demonstrated, with 294 
improved design, the approach has clear therapeutic potential (Szynol, et al., 2006). In the 295 
MRSA field, the further development of cationic peptides for systemic use as targeted 296 
candidates against MRSA will depend on the selection of appropriate effective, 297 
candidates that are amenable to chemical modification and the design of bacterial or site 298 
of infection-mediated targeting approaches.  299 
Another limitation to the therapeutic application of peptide based anti-infectives is 300 
the high cost associated with chemical synthesis in large quantities. Synthetic mimics of 301 
antimicrobial peptides that have an unnatural backbone but maintain the biophysical 302 
characteristics of CAMPs offer a cost advantage (Rotem & Mor, 2009).  Recently  the 303 
economic feasibility of chemical synthesis on a multi-tonne scale has been demonstrated 304 
for the biomimetic anti-retroviral agent, enfuvirtide (Bray, 2003).  Large-scale 305 
recombinant production of the fungal defensin, plectasin, has been achieved at 306 
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commercially viable yield and purity, from cultures of the yeast, Aspergillus oryzae 307 
(Mygind, et al., 2005). Methodologies for large-scale industrial production of seven 308 
recombinant host defence peptides representative of those that are currently undergoing 309 
clinical trials, have recently been developed by fusion to sumoase protease (SUMO), 310 
cloning into E. coli and a two step purification of the fusion product from the culture. 311 
This expression system gave high yields of intact and biologically active peptides and has 312 
demonstrated a cost-effective means of HDP production under good laboratory 313 
manufacturing processes (GMP) that would be required for human therapeutic 314 
applications (Bommarius, et al., 2010).  315 
 316 
THERAPEUTIC APPROACHES THAT TARGET MRSA VIRULENCE 317 
Another novel approach to the development of anti-staphylococcal agents with 318 
reduced capacity to elicit bacterial resistance is the development of ‘anti-pathogenic’ 319 
agents. These agents are designed to interfere with bacterial virulence mechanisms 320 
including binding to host tissues, evasion of phagocytosis, biofilm production and the 321 
production of toxins. The limited anti-bacterial activity of such agents may minimise the 322 
development of resistance while controlling the pathogenic process through diminished 323 
bacterial virulence.  Controlling pathogenic processes in this way, may allow the host 324 
immune response to more effectively overcome the infection. However, these agents 325 
could serve as adjuncts for immunocompromised patients. This anti-pathogenic approach, 326 
which relies on the identification and characterisation of appropriate virulence targets, has 327 
been an academic research pursuit for over two decades. Promising targets that may be 328 
disrupted amongst S. aureus, in the development of novel anti-pathogenic drugs include 329 
the accessory gene regulator (agr), sortase enzyme system, the carotenoid biosynthetic 330 
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pathway and other recently discovered regulatory pathways.  These systems contribute to 331 
the ability of S. aureus to effectively invade and damage the host and therefore their 332 
modulation represents a novel strategy in the anti-infective field and should be further 333 
explored. 334 
 335 
THE QUORUM SENSING RESPONSE 336 
The quorum-sensing response in S. aureus describes the coordinated expression of 337 
virulence genes in response to bacterial cell density and is modulated by complex 338 
regulatory systems, the best characterised of which is the accessory gene regulator (agr).  339 
Agr modulation contributes to the expression of a variety of virulence genes at different 340 
stages of infection through quorum sensing auto-inducing peptide (AIP) signals.    341 
(Novick, 2003, Cheung, et al., 2004). This role for agr in the inverse coordinated 342 
expression of genes that promote colonization and invasion has prompted many 343 
researchers to pursue agr as an anti-virulence target. Specific molecules in the agr 344 
system, AIP and RNAIII (the effector molecule) have been investigated as potential 345 
targets for inhibition (Dell'Acqua, et al., 2004, Qazi, et al., 2006, Balaban, et al., 2007, 346 
George, et al., 2008).  A global inhibitor of S. aureus AIPs was designed based on 347 
structure-function analysis and consists of a truncated thiolactone region of AIP-II (Lyon, 348 
et al., 2000) and more recently investigations of a series of synthetic mimetics of this 349 
region have revealed the minimum structural requirements for inhibition (George, et al., 350 
2008).  Early administration of an AIP analogue  attenuated abscess formation  in a 351 
mouse subcutaneous abscess model but based on their findings,  the authors suggest that 352 
administration of such quorum sensing inhibitors for S. aureus infections may be only of 353 
prophylactic value based on the kinetics of AIP activation (Wright, et al., 2005).  354 
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The potential of targeting agr for the treatment of device-related infections, which 355 
are difficult to treat with conventional antibiotics due to biofilm production, has been 356 
demonstrated by inhibition of this regulatory system with RNAIII-inhibiting peptide 357 
(RIP). This peptide caused a significant dose and duration-dependent reduction in 358 
bacterial load in MRSA graft infections in rats, which was further reduced when RIP was 359 
administered in combination with teicoplanin (Balaban, et al., 2007, Simonetti, et al., 360 
2008). The therapeutic efficacy and safety of RIP and two synthetic analogues of RIP 361 
have also been shown in histopathological studies in a mouse model of S. aureus sepsis 362 
(Ribeiro, et al., 2003). Although the target of RNAIII activating peptide (TRAP) has 363 
controversially been shown not to function in S. aureus pathogenesis (Shaw, et al., 2007), 364 
RIP has been shown to reduce staphylococcal infection in several in-vivo models of 365 
infection and no toxicity has been noted. With regard to biofilm dispersal however, it has 366 
conversely been shown in-vitro, that agr inhibition is required for biofilm formation and 367 
biofilm dispersal has been demonstrated with the addition of AIP to up-regulate agr-368 
induced protease production (Boles & Horswill, 2008).  369 
 370 
 More recently the non-ribosomal secondary metabolite, aureusamine was 371 
reported to regulate virulence gene expression and the isogenic ausA mutant, which failed 372 
to haemolyse blood agar, had attenuated virulence in a mouse model of infection 373 
compared to the wild-type strain (Wyatt, et al.).  This reported role for aureusamine in 374 
virulence gene regulation was later found to be due to an inadvertent mutation in the 375 
SaeR two component regulator system (Sun, et al., 2011).  The controversies surrounding 376 
the genetic stability of the agr locus in laboratory strains and the complexity of the roles 377 
of RIP, AIP and aureusamine in S. aureus pathogenesis has hampered progress in 378 
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targeting quorum sensing systems for the discovery of novel anti-infectives. Nonetheless 379 
these studies have been important in demonstrating the therapeutic potential of targeting 380 
virulence mechanisms and have prompted the study of other pleiotrophic regulators. With 381 
regard to novel therapeutic agents to inhibit agr-mediated virulence expression, the 382 
discovery of new molecules may be advanced due to the development of a simple, 383 
inexpensive assay to allow screening of large numbers of molecules for their effects on S. 384 
aureus virulence.  This system is based on the observation of colour changes in response 385 
to the candidate molecule, in the growth media of S. aureus strains with lacZ fusions to 386 
the agr-regulated genes, spa and hla, in the presence of a beta-galactosidase substrate 387 
(Nielsen, et al., 2010) 388 
.   389 
S. AUREUS SORTASE ENZYMES 390 
Attachment of S. aureus to host endothelial tissue is facilitated by proteins that 391 
recognise specific tissue components such as fibrinogen, fibrin and collagen.  The activity 392 
of these, so called microbial surface components recognising adhesive matrix molecules 393 
(MSCRAMMS) is dependent on their covalent attachment to bacterial peptidoglycan.  394 
The anchoring of these molecules to the cell wall is catalysed by a group of cysteine 395 
transpeptidases called the sortase enzymes (Figure 3), which in S. aureus include two 396 
isoforms, SrtA and SrtB (Mazmanian, et al., 1999, Mazmanian, et al., 2002). SrtA is 397 
constitutively expressed while SrtB is expressed in response to low iron conditions. 398 
Deletion of the sortase A gene (srtA) in S. aureus, results in failure to display 399 
MSCRAMMs and therefore attachment to host components including IgG, fibronectin 400 
and fibrinogen.  In a mouse model of S. aureus infection, mutants lacking srtA had a 2 log 401 
reduction in bacterial growth in multiple organs and a 1.5 log increase in lethal dose 402 
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compared to the wild type (Mazmanian, et al., 2000). Later investigations demonstrated 403 
that srtA knock-out mutants showed reduced virulence in models of septic arthritis and 404 
endocarditis (Jonsson, et al., 2003, Weiss, et al., 2004).  405 
 It has been recently shown that disruption of srtA in five biofilm-producing 406 
clinical isolates of MRSA results in significant reduction (up to six fold) in glucose-407 
induced biofilm formation which can be reversed by complementation (O'Neill, et al., 408 
2008). The SrtB enzyme has a role specifically in the attachment of iron acquisition 409 
proteins such as IsdA, isdB etc and mutants that lack the SrtB gene are also associated 410 
with reduced virulence in the mouse model of septic arthritis but only in the later stages 411 
of infection when iron is limited in the environment (Jonsson, et al., 2003).  412 
The pathogenesis of S. aureus in persistent infections is linked to its ability to 413 
survive within macrophages where it is protected from the host immune response.  414 
Expression of SrtA has also been shown to be critical to phagosomal survival of S. aureus 415 
as SrtA mutants are efficiently killed by macrophages (Kubica, et al., 2008). These 416 
studies suggest that SrtA specifically may be a potential target for the development of 417 
novel anti-infective agents and may have specific application for complicated or 418 
persistent S. aureus infection including those involving biofilms. Selective toxicity by 419 
sortase inhibition is possible as there is no related sortase homologue in eukaryotic cells. 420 
The localisation of SrtA within the cell-membrane of S. aureus and other Gram-positive 421 
organisms offers an advantage in terms of the ease of access to this target where the 422 
activity of potential inhibitors will not rely on transport across the cell envelope.  It has 423 
been speculated that bacterial resistance to sortase inhibition would be reduced compared 424 
to classical antibiotics given that SrtA mutants have similar growth rates to the wild type 425 
(Weiss, et al., 2004). The lack of disruption to essential gene function by SrtA mutation 426 
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or inhibition, together with significantly attenuated virulence potential associated with 427 
loss of sortase activity suggests that selective pressure would not be as significant for 428 
these possible agents as it is for antibiotics such as penicillin or aminoglycosides where 429 
the target is essential for cell survival and where selective pressure would favour the 430 
development of resistance. Numerous molecules have been investigated as potential 431 
inhibitors of sortase enzymes.  Some of the most promising of these have been discovered 432 
by small molecule screening and were selected based on their ‘drug-like’ structures.  For 433 
example, Oh and colleagues discovered a novel class of S. aureus sortase inhibitors, the 434 
diarylacrylonitriles, from a library of 1000 small molecules. Modification of the lead 435 
compound from the initial screen, resulted in a reduction in  IC50 from 231 M to 9.244 436 
M (Oh, et al., 2004).  These authors have further shown that this molecule, (Z)-3-(2,5-437 
dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) was effective in an in-438 
vivo mouse model of S. aureus infection. Survival rates increased and joint and bone 439 
infections decreased in the treated animals compared to controls (Oh, et al., 2010). The 440 
aryl (-amino) ethyl ketones (AAEKs) were also selected from a large screening library 441 
of small molecules.  These are mechanism-based enzyme inhibitors that have selectivity 442 
for S. aureus SrtA  with IC50 and Ki values in the low micromolar range (lead compounds 443 
IC50 15-47 M) (Maresso, et al., 2007).  More recently, pyridazinone and pyrazolethione 444 
analogues, selected from over 300,000 small molecules, have been shown to reversibly 445 
inhibit SrtA with IC50s in the high nanomolar range (Suree, et al., 2009).  446 
Sortase remains an attractive candidate as an antivirulence target and the 447 
discovery of several distinct sortase inhibitors with activities in the nano- to micro-molar 448 
range and with drug-like properties is encouraging. However, challenges remain that 449 
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require further investigation. The inhibition of sortase enzymes, by preventing the display 450 
of surface antigen, may dampen the host immune response which is required for bacterial 451 
clearance.  Furthermore, bacterial clearance, even for virulence attenuated bacteria, 452 
requires active opsonophagocytic killing which may be impaired in the 453 
immunocompromised patient. A pharmacological evaluation of sortase inhibitors should 454 
be carried out, to assess therapeutic efficacy and toxicity. Further discoveries are needed 455 
to increase the pool of molecules available for further investigation as potential 456 
therapeutic agents. The further advancement of these discoveries will be initially guided 457 
by their properties in in-vivo models of infection.  458 
 459 
STAPHYLOXANTHIN BIOSYNTHESIS 460 
The antioxidant properties of the carotenoid pigment, staphyloxanthin, responsible 461 
for the golden colour of S. aureus, protects the organism from reactive oxygen species 462 
produced by neutrophils (Liu, et al., 2005). This finding suggests that modulation of this 463 
metabolic pathway may have anti-pathogenic effects. In a mouse subcutaneous model of 464 
infection, mice infected with S. aureus mutants lacking this pigment have significantly 465 
reduced bacterial loads and no visible lesions compared to the wild-type strain (Liu, et 466 
al., 2005). Increased bacterial clearance of staphyloxanthin mutant compared to the wild-467 
type was also shown by these authors in a murine model of nasal colonization (Liu, et al., 468 
2008).  469 
One of the key enzymes in staphyloxanthin biosynthesis is S. aureus
 
470 
dehydrosqualene synthase (SQS or CrtM) which catalyses the condensation of two 471 
molecules of isoprenoid farnesyl disphosphate to form dehydrosqualene. Interestingly, 472 
there is overlap between the early steps of staphyloxanthin biosynthesis and human 473 
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cholesterol biosynthesis. Human SQS and the bacterial enzyme CrtM have 30 % 474 
sequence identity but have been shown to share significant structural features (Liu, et al., 475 
2008). Furthermore, compounds originally developed as cholesterol-lowering agents have 476 
been shown to inhibit S. aureus CrtM in the nanomolar range and have been investigated 477 
as potential anti-pathogenic agents (Liu, et al., 2008). Two cholesterol lowering agents, 478 
lapaquistat acetate and squalestatin interact with both human squalene synthase and S. 479 
aureus CrtM at specific common residues (Kahlon, et al., 2010). Among the most potent 480 
inhibitors of CrtM that also prevent staphyloxanthin formation in cellular assays, are the 481 
phosphosulphonates with Ki in the range 1.5-135 nM and the diphenyl ether 482 
phosphonoacetamides with Ki in the range 30-70 nM. The most potent of the 483 
phosphosulphonates (designated BPH652) was further tested because it had advanced 484 
through preclinical animal testing and two human clinical trials as a cholesterol-lowering 485 
agent (Sharma, et al., 1998a, Sharma, et al., 1998b). No inhibition of the growth of three 486 
human cell-lines was found up to a concentration of 300 M BPH652.  The in-vivo 487 
activity of BPH652 has also been determined in a mouse model of systemic S. aureus 488 
infection and 96 % reduction in S. aureus colony forming units was achieved in the 489 
treated group (Song, et al., 2009).  The question of selectivity for the S. aureus CrtM over 490 
human SQS has also been addressed by these authors and several halogen-substituted 491 
derivatives show selectivity for the bacterial enzyme (Song, et al., 2009).  492 
The diphenyl ether phosphonoacetamides have further improved properties in 493 
terms of their uptake into cells (IC50 = 8nM) while retaining their selectivity for the 494 
bacterial enzyme and their negligible toxicity in human cell lines (Song, et al., 2009). The 495 
inhibition of the staphyloxanthin pathway in S. aureus, as anti-virulence agents is 496 
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attractive, because many cholesterol-lowering agents have previously undergone clinical 497 
trials and their toxicities and pharmacokinetic properties are already known (Liu, et al., 498 
2008). Further testing of the improved molecules described above, in animal infection 499 
models will be eagerly awaited.  500 
The pigmentation of S. aureus due to staphyloxanthin can be exploited in the 501 
development of technologies for rapid screening of candidate inhibitory molecules and 502 
one such system has been used successfully to identify at least four known inhibitors of 503 
lipid metabolism that reduce staphyloxanthin pigmentation, from a natural compounds 504 
library (Sakai, et al., 2012). 505 
 506 
 507 
CONCLUSION 508 
 The anti-infectives industry appears to rely on the development of further 509 
generations of conventional antibiotics which have improved properties but do not offer 510 
new modes of action. Here, we have highlighted areas where basic and applied research 511 
has demonstrated the potential of novel anti-MRSA therapies.  It is clear however that 512 
further research is required to determine when and how these compounds can be 513 
administered. Investment in generating convincing in-vivo data that supports a protective 514 
role for novel therapeutic agents with minimum side-effects is required.   Given that the 515 
majority of patients requiring therapeutic intervention for S. aureus infection are 516 
immunocompromised, it appears that both of the approaches discussed here, would have 517 
potential as adjuvant therapies rather than their exclusive use as anti-infectives. It is 518 
interesting therefore, that synergistic in-vitro and in-vivo effects have been reported using 519 
a combination of two HDPs and vancomycin (Cirioni, et al., 2006) and a potential 520 
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advantage of the administration of pexiganan with -lactam antibiotics has also been 521 
demonstrated (Giacometti, et al., 2005).  These combined applications would potentially 522 
extend the therapeutic effectiveness of current antibiotics. Anti-virulence approaches, 523 
aimed at modulating the pathogenic effects of S. aureus infection, could also be 524 
investigated in conjunction with conventional antibiotics.  525 
 526 
Figure Legends 527 
 528 
 529 
 530 
Figure 1. New MRSA agents in clinical use (*) and MRSA agents in development  531 
 532 
 533 
 534 
Figure 2. Dual effects of host defence peptides  535 
 536 
Host defence peptides can exert anti-bacterial effects directly by forming pores in the cell 537 
membrane or can modulate the immune response to infection by inducing transcription of 538 
cytokines or directing cellular components of the immune system such as neutrophils, 539 
dendritic cells, monocytes and macrophages  to the site of infection.  540 
 541 
 542 
Figure  3. Mechanism of sortase processing of MSCRAAMS.  Sortase B cleaves at the 543 
LPXTG motif to allow display of MSCRAAMS at cell surface.  Their display facilitates 544 
adhesion to host cells. If sortase is inhibited, the bacterial cell has reduced adhesion to the 545 
host cell as the surface adhesins are not displayed.  546 
IL8 547 
 548 
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Table 1.  Examples of natural cationic peptides with potential for development as S. aureus anti-infectives 555 
 
Peptide Name 
 
Source 
 
Amino acid sequence  
 
 
Proposed mechanism 
 
MIC in mg/L
 a
 
 
 
Stage of development 
      
Buforin II Asian Toad (Bufo 
bufo gargarizans) 
stomach 
 
TRSSRAGLQWPVGRVHRL
LRK 
 
Translocation and interaction with nucleic 
acids (Park, et al., 1998) 
8
b
 (Giacometti, 
et al., 2000) 
Pre-clinical 
LL-37 Human (neutrophils 
and epithelial cells) 
LLGDFFRKSKEKIGKEFKR
IVQRIKDFLRNLVPRTES 
 
Translocation and interaction with 
intracellular target. Monocyte, T-cell, 
neutrophil chemotaxis 
31 (Bals, et al., 
1998) 
Pre-clinical 
Bac8c Synthetic derivative 
of bactenecin from 
bovine neutrophils 
RIWVIWRR 
 
Membrane depolarisation and cytoplamic 
permeabilization (Spindler, et al., 2011) 
2 (Hilpert, et 
al., 2005) 
Pre-clinical 
Temporin10a Frog (Rana 
ornativentris) skin 
 
FLPLASLFSRLL 
 
Pore formation, membrane depolarization 
(Kim, et al., 2001) 
0.014 
c
(Kim, et 
al., 2001) 
Pre-clinical 
Syphaxin (SPX1-
22) 
Frog (Leptodactylus 
syphax) skin 
 
GVLDILKGAAKDLAGHVA
TKVINKI 
 
Not elucidated 31.9
 c
 
(Dourado, et 
al., 2007) 
Pre-clinical 
Iseganan 
(IB-367) 
Derivative of 
protegrin from  
porcine neutrophils 
RGGLCYCRGRFCVCVGR 
 
Pore formation, membrane depolarizaton 
(Sokolov, et al., 1999) 
4 (Mosca, et 
al., 2000) 
Treatment of oral 
mucositis. Phase III 
clinical trials 
Pexiganan (MSI-
78)  
Magainan analogue GIGKFLKKAKKFGKAFVKI
LKK 
Cell membrane disruption and pore 
formation 
16-64 
d
(Fuchs, 
et al., 1998) 
Topical treatment of 
diabetic foot ulcers. 
Phase III clinical trials  
PMX-30063D Defensin peptide 
mimetic 
n/a Membrane disruption ≤ 2 e Acute SSTI. Phase II 
clinical trials 
 556 
 557 
a 
Clinical Laboratory
 
Standards Institute (CLSI) broth microdilution method with modifications, unless indicated otherwise. 558 
 b
 90% inhibition, standard CLSI methods.  559 
c
 Units have been converted from M to mg/L 560 
d 
Mean MIC at which 90 % of S. aureus (n=10) or MRSA (n=15) isolates were inhibited  561 
 562 
e
 http://irgnews.com/sites/default/themes/publisher/images/companies/PYMX/PYMX-PMX-30063_fs.pdf 563 
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Cell wall active agents
Ceftobiprole
Ceftaroline
Dalvabancin
Oritavancin
Protein synthesis 
inhibitors
Streptogramins*
Linezolid*
Tigecycline*
RX-1741
Folate synthesis inhibitor
Iclaprim  564 
 565 
Figure 1 566 
 567 
568 
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T-cell 
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570 
29 
 

L
P
X
T
G 
L
P
X
T
G 
L
P
X
T
G
Inhibition of  sortase  to prevent cell 
adhesion by loss of display of 
MSCRAAMS on bacterial surface
Host cell
Cell wall
Cell 
membrane
Sortase enzyme
L
P
X
T
Cell-wall anchored MSCRAAM (eg 
fibronectin binding protein, collagen 
binding adhesin)
Specific MSCRAAM 
receptors
L
P
X
T
G
Unprocessed 
MSCRAAM
L
P
X
T
  
L
P
X
T
  
571 
30 
 
REFERENCES 572 
 573 
Augustin R, Anton-Erxleben F, Jungnickel S, Hemmrich G, Spudy B, Podschun R & 574 
Bosch TC (2009) Activity of the novel peptide arminin against multiresistant human 575 
pathogens shows the considerable potential of phylogenetically ancient organisms as drug 576 
sources. Antimicrob Agents Chemother 53: 5245-5250. 577 
Balaban N, Cirioni O, Giacometti A, et al. (2007) Treatment of Staphylococcus aureus 578 
biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 51: 579 
2226-2229. 580 
Bals R, Wang X, Zasloff M & Wilson JM (1998) The peptide antibiotic LL-37/hCAP-18 581 
is expressed in epithelia of the human lung where it has broad antimicrobial activity at the 582 
airway surface. Proc Natl Acad Sci U S A 95: 9541-9546. 583 
Baltz RH (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic 584 
engineering. Curr Opin Chem Biol 13: 144-151. 585 
Boles BR & Horswill AR (2008) Agr-mediated dispersal of Staphylococcus aureus 586 
biofilms. PLoS Pathog 4: e1000052. 587 
Bommarius B, Jenssen H, Elliott M, et al. (2010) Cost-effective expression and 588 
purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 31: 589 
1957-1965. 590 
Bowdish DM, Davidson DJ & Hancock RE (2006) Immunomodulatory properties of 591 
defensins and cathelicidins. Curr Top Microbiol Immunol 306: 27-66. 592 
Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG & Hancock RE (2005) Impact of 593 
LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459. 594 
Bray BL (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. 595 
Nat Rev Drug Discov 2: 587-593. 596 
Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK & Saavedra JE 597 
(2008) Synthesis, mechanistic studies, and anti-proliferative activity of 598 
glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorganic & 599 
Medicinal Chemistry 16: 9764-9771. 600 
31 
 
Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML & Hodges RS (2005) Rational 601 
design of alpha-helical antimicrobial peptides with enhanced activities and 602 
specificity/therapeutic index. J  Biol  Chem 280: 12316-12329. 603 
Cheung AL, Bayer AS, Zhang G, Gresham H & Xiong YQ (2004) Regulation of 604 
virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol 605 
Med Microbiol 40: 1-9. 606 
Cirioni O, Silvestri C, Ghiselli R, et al. (2006) Experimental study on the efficacy of 607 
combination of alpha-helical antimicrobial peptides and vancomycin against 608 
Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 27: 2600-609 
2606. 610 
Dai C, Ma Y, Zhao Z, et al. (2008) Mucroporin, the first cationic host defense peptide 611 
from the venom of Lychas mucronatus. Antimicrob Agents Chemother 52: 3967-3972. 612 
Dathe M, Wieprecht T, Nikolenko H, et al. (1997) Hydrophobicity, hydrophobic moment 613 
and angle subtended by charged residues modulate antibacterial and haemolytic activity 614 
of amphipathic helical peptides. FEBS Lett 403: 208-212. 615 
Dauner DG, Nelson RE & Taketa DC (2010) Ceftobiprole: A novel, broad-spectrum 616 
cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J 617 
Health Syst Pharm 67: 983-993. 618 
Dean SN, Bishop BM & van Hoek ML (2011) Natural and synthetic cathelicidin peptides 619 
with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC 620 
Microbiol 11: 114. 621 
Dell'Acqua G, Giacometti A, Cirioni O, et al. (2004) Suppression of drug-resistant 622 
Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J  623 
Infect  Dis 190: 318-320. 624 
Dourado FS, Leite JR, Silva LP, Melo JA, Bloch C, Jr. & Schwartz EF (2007) 625 
Antimicrobial peptide from the skin secretion of the frog Leptodactylus syphax. Toxicon 626 
50: 572-580. 627 
Ellerby HM, Arap W, Ellerby LM, et al. (1999) Anti-cancer activity of targeted pro-628 
apoptotic peptides. Nat Med 5: 1032-1038. 629 
32 
 
Ernst CM, Staubitz P, Mishra NN, et al. (2009) The bacterial defensin resistance protein 630 
MprF consists of separable domains for lipid lysinylation and antimicrobial peptide 631 
repulsion. PLoS Pathog 5: e1000660. 632 
Fluit AC, Wielders CL, Verhoef J & Schmitz FJ (2001) Epidemiology and susceptibility 633 
of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the 634 
European SENTRY study. J Clin Microbiol 39: 3727-3732. 635 
Fuchs PC, Barry AL & Brown SD (1998) In vitro antimicrobial activity of MSI-78, a 636 
magainin analog. Antimicrob Agents Chemother 42: 1213-1216. 637 
George EA, Novick RP & Muir TW (2008) Cyclic peptide inhibitors of staphylococcal 638 
virulence prepared by Fmoc-based thiolactone peptide synthesis. J Am Chem Soc 130: 639 
4914-4924. 640 
Giacometti A, Cirioni O, Del Prete MS, Paggi AM, D'Errico MM & Scalise G (2000) 641 
Combination studies between polycationic peptides and clinically used antibiotics against 642 
Gram-positive and Gram-negative bacteria. Peptides 21: 1155-1160. 643 
Giacometti A, Cirioni O, Kamysz W, et al. (2005) In vitro activity of MSI-78 alone and 644 
in combination with antibiotics against bacteria responsible for bloodstream infections in 645 
neutropenic patients. Int J Antimicrob Agents 26: 235-240. 646 
Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T & Peters G (2012) New 647 
insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment 648 
and resistance. Int J Antimicrob Agents 39: 96-104. 649 
Hadley EB & Hancock RE (2010) Strategies for the discovery and advancement of novel 650 
cationic antimicrobial peptides. Curr Top Med Chem 10: 1872-1881. 651 
Hamamoto K, Kida Y, Zhang Y, Shimizu T & Kuwano K (2002) Antimicrobial activity 652 
and stability to proteolysis of small linear cationic peptides with D-amino acid 653 
substitutions. Microbiol Immunol 46: 741-749. 654 
Hancock RE & Patrzykat A (2002) Clinical development of cationic antimicrobial 655 
peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2: 79-83. 656 
Hancock RE & Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-657 
infective therapeutic strategies. Nat Biotechnol 24: 1551-1557. 658 
33 
 
Hartman BJ & Tomasz A (1984) Low-affinity penicillin-binding protein associated with 659 
beta-lactam resistance in Staphylococcus aureus. J Bacteriol 158: 513-516. 660 
Hilpert K, Volkmer-Engert R, Walter T & Hancock REW (2005) High-throughput 661 
generation of small antibacterial peptides with improved activity. Nat. Biotech. 23: 1008-662 
1012. 663 
Hong SY, Oh JE & Lee KH (1999) Effect of D-amino acid substitution on the stability, 664 
the secondary structure,  and the activity of membrane-active peptide. Biochem 665 
Pharmacol. 58: 1775-1780. 666 
Imura Y, Nishida M, Ogawa Y, Takakura Y & Matsuzaki K (2007) Action mechanism of 667 
tachyplesin I and effects of PEGylation. Biochim Biophys Acta 1768: 1160-1169. 668 
Jia L, Noker PE, Piazza GA, et al. (2008) Pharmacokinetics and pharmacodynamics of 669 
Phor21-betaCG(ala), a lytic peptide conjugate. J Pharm Pharmacol 60: 1441-1448. 670 
Jonsson IM, Mazmanian SK, Schneewind O, Bremell T & Tarkowski A (2003) The role 671 
of Staphylococcus aureus sortase A and sortase B in murine arthritis. Microbes Infect 5: 672 
775-780. 673 
Kahlon AK, Roy S & Sharma A (2010) Molecular docking studies to map the binding 674 
site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus 675 
aureus. J Biomol Struct Dyn 28: 201-210. 676 
Kim JB, Iwamuro S, Knoop FC & Conlon JM (2001) Antimicrobial peptides from the 677 
skin of the Japanese mountain brown frog, Rana ornativentris. J Pept Res 58: 349-356. 678 
Kubica M, Guzik K, Koziel J, et al. (2008) A potential new pathway for Staphylococcus 679 
aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-680 
derived macrophages. PLoS One 3: e1409. 681 
Li M, Diep BA, Villaruz AE, et al. (2009) Evolution of virulence in epidemic 682 
community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U 683 
S A 106: 5883-5888. 684 
Li Q, Zhou Y, Dong K & Guo X (2010) Potential therapeutic efficacy of a bactericidal-685 
immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus 686 
skin infection. Appl Microbiol Biotechnol 86: 305-309. 687 
34 
 
Li Q, Zhou Y, Dong K & Guo X (2010) Potential therapeutic efficacy of a bactericidal–688 
immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus 689 
skin infection. Applied Microbiology and Biotechnology 86: 305-309. 690 
Liu C, Bayer A, Cosgrove SE, et al. (2011) Clinical Practice Guidelines by the Infectious 691 
Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus 692 
aureus Infections in Adults and Children. Clinical Infectious Diseases 52: e18-e55. 693 
Liu CI, Liu GY, Song Y, et al. (2008) A cholesterol biosynthesis inhibitor blocks 694 
Staphylococcus aureus virulence. Science 319: 1391-1394. 695 
Liu GY, Essex A, Buchanan JT, et al. (2005) Staphylococcus aureus golden pigment 696 
impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp 697 
Med 202: 209-215. 698 
Lyon GJ, Mayville P, Muir T & Novick RP (2000) Rational design of a global inhibitor 699 
of the virulence response in Staphylococcus aureus, based in part on localization of the 700 
site of inhibition to the receptor-histidine kinase, AgrC. PNAS 97: 13330-13335. 701 
Mader JS & Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents 702 
for cancer treatment. Expert Opin Investig Drug 15: 933-946. 703 
Maresso AW, Wu R, Kern JW, et al. (2007) Activation of inhibitors by sortase triggers 704 
irreversible modification of the active site. J Biol Chem 282: 23129-23139. 705 
Marks AJ, Cooper MS, Anderson RJ, et al. (2005) Selective apoptotic killing of 706 
malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. 707 
Cancer Res 65: 2373-2377. 708 
Mazmanian SK, Liu G, Ton-That H & Schneewind O (1999) Staphylococcus aureus 709 
sortase, an enzyme that anchors surface proteins to the cell wall. Science 285: 760-763. 710 
Mazmanian SK, Ton-That H, Su K & Schneewind O (2002) An iron-regulated sortase 711 
anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc Natl 712 
Acad Sci U S A 99: 2293-2298. 713 
Mazmanian SK, Liu G, Jensen ER, Lenoy E & Schneewind O (2000) Staphylococcus 714 
aureus sortase mutants defective in the display of surface proteins and in the pathogenesis 715 
of animal infections. Proc Natl Acad Sci U S A 97: 5510-5515. 716 
35 
 
Mookherjee N, Brown KL, Bowdish DM, et al. (2006) Modulation of the TLR-mediated 717 
inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 718 
176: 2455-2464. 719 
Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA & Falla TJ (2000) IB-367, a protegrin 720 
peptide with in vitro and in vivo activities against the microflora associated with oral 721 
mucositis. Antimicrob. Agents Chemother. 44: 1803-1808. 722 
Mygind PH, Fischer RL, Schnorr KM, et al. (2005) Plectasin is a peptide antibiotic with 723 
therapeutic potential from a saprophytic fungus. Nature 437: 975-980. 724 
Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW & Grote JJ 725 
(2006) Development of novel LL-37 derived antimicrobial peptides with LPS and LTA 726 
neutralizing and antimicrobial activities for therapeutic application. Peptides 27: 649-660. 727 
Nielsen A, Nielsen KF, Frees D, Larsen TO & Ingmer H (2010) Method for screening 728 
compounds that influence virulence gene expression in Staphylococcus aureus. 729 
Antimicrob Agents Chemother 54: 509-512. 730 
Nijnik A, Madera L, Ma S, et al. (2010) Synthetic cationic peptide IDR-1002 provides 731 
protection against bacterial infections through chemokine induction and enhanced 732 
leukocyte recruitment. J Immunol 184: 2539-2550. 733 
Novick RP (2003) Autoinduction and signal transduction in the regulation of 734 
staphylococcal virulence. Mol Microbiol 48: 1429-1449. 735 
O'Neill E, Pozzi C, Houston P, et al. (2008) A novel Staphylococcus aureus biofilm 736 
phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol 737 
190: 3835-3850. 738 
Oh KB, Kim SH, Lee J, Cho WJ, Lee T & Kim S (2004) Discovery of diarylacrylonitriles 739 
as a novel series of small molecule sortase A inhibitors. J Med Chem 47: 2418-2421. 740 
Oh KB, Nam KW, Ahn H, Shin J, Kim S & Mar W (2010) Therapeutic effect of (Z)-3-741 
(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) against 742 
Staphylococcus aureus infection in a murine model. Biochem Biophys Res Commun 396: 743 
440-444. 744 
36 
 
Panyutich AV, Voitenok NN, Lehrer RI & Ganz T (1991) An enzyme immunoassay for 745 
human defensins. J Immunol Methods 141: 149-155. 746 
Park CB, Kim HS & Kim SC (1998) Mechanism of action of the antimicrobial peptide 747 
buforin II: buforin II kills microorganisms by penetrating the cell membrane and 748 
inhibiting cellular functions. Biochem Biophys Res Commun 244: 253-257. 749 
Peschel A, Jack RW, Otto M, et al. (2001) Staphylococcus aureus resistance to human 750 
defensins and evasion of neutrophil killing via the novel virulence factor MprF is based 751 
on modification of membrane lipids with l-lysine. J Exp Med 193: 1067-1076. 752 
Prabhu K, Rao S & Rao V (2011) Inducible Clindamycin Resistance in Staphylococcus 753 
aureus Isolated from Clinical Samples. J Lab Physicians 3: 25-27. 754 
Qazi S, Middleton B, Muharram SH, et al. (2006) N-acylhomoserine lactones antagonize 755 
virulence gene expression and quorum sensing in Staphylococcus aureus. Infect Immun 756 
74: 910-919. 757 
Reynolds PE & Brown DF (1985) Penicillin-binding proteins of beta-lactam-resistant 758 
strains of Staphylococcus aureus. Effect of growth conditions. FEBS Lett 192: 28-32. 759 
Ribeiro PD, Ribeiro OD, Marcolan AM & Medina-Acosta E (2003) Treatment efficacy of 760 
the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus 761 
sepsis: a histopathological assessment. Peptides 24: 1829-1836. 762 
Rotem S & Mor A (2009) Antimicrobial peptide mimics for improved therapeutic 763 
properties. Biochim Biophys Acta 1788: 1582-1592. 764 
Ruiz de Gopegui E, Juan C, Zamorano L, Perez JL & Oliver A (2012) Transferable 765 
multidrug resistance plasmid carrying cfr associated with tet(L), ant(4' )-Ia and dfrK 766 
genes from a clinical methicillin-resistant Staphylococcus aureus ST125 strain. 767 
Antimicrob Agents Chemother. 768 
Sader HS, Fedler KA, Rennie RP, Stevens S & Jones RN (2004) Omiganan 769 
pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of 770 
antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents 771 
Chemother 48: 3112-3118. 772 
37 
 
Sadler K, Eom KD, Yang JL, Dimitrova Y & Tam JP (2002) Translocating proline-rich 773 
peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41: 14150-14157. 774 
Sakai K, Koyama N, Fukuda T, Mori Y, Onaka H & Tomoda H (2012) Search method 775 
for inhibitors of Staphyloxanthin production by methicillin-resistant Staphylococcus 776 
aureus. Biol Pharm Bull 35: 48-53. 777 
Scott MG, Dullaghan E, Mookherjee N, et al. (2007) An anti-infective peptide that 778 
selectively modulates the innate immune response. Nat Biotechnol 25: 465-472. 779 
Sharma A, Slugg PH, Hammett JL & Jusko WJ (1998a) Clinical pharmacokinetics and 780 
pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy 781 
volunteers. J Clin Pharmacol 38: 1116-1121. 782 
Sharma A, Slugg PH, Hammett JL & Jusko WJ (1998b) Estimation of oral bioavailability 783 
of a long half-life drug in healthy subjects. Pharm Res 15: 1782-1786. 784 
Shaw LN, Jonsson IM, Singh VK, Tarkowski A & Stewart GC (2007) Inactivation of 785 
traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus 786 
aureus. Infect Immun 75: 4519-4527. 787 
Shimazaki K, Nam MS, Harakawa S, et al. (1996) Monoclonal antibody against bovine 788 
Lactoferricin and its epitopic site. J Vet Med Sci 58: 1227-1229. 789 
Simonetti O, Cirioni O, Ghiselli R, et al. (2008) RNAIII-inhibiting peptide enhances 790 
healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob 791 
Agents Chemother 52: 2205-2211. 792 
Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI & Kagan BL (1999) Membrane 793 
channel formation by antimicrobial protegrins. Biochim Biophys Acta 1420: 23-29. 794 
Song S, Liu D, Peng J, et al. (2009) Novel peptide ligand directs liposomes toward EGF-795 
R high-expressing cancer cells in vitro and in vivo. FASEB J 23: 1396-1404. 796 
Song Y, Lin FY, Yin F, et al. (2009) Phosphonosulfonates are potent, selective inhibitors 797 
of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. 798 
J Med Chem 52: 976-988. 799 
38 
 
Song Y, Liu CI, Lin FY, et al. (2009) Inhibition of staphyloxanthin virulence factor 800 
biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J 801 
Med Chem 52: 3869-3880. 802 
Sorensen O, Cowland JB, Askaa J & Borregaard N (1997) An ELISA for hCAP-18, the 803 
cathelicidin present in human neutrophils and plasma. J Immunol Methods 206: 53-59. 804 
Soriano A, Marco F, Martinez JA, et al. (2008) Influence of vancomycin minimum 805 
inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus 806 
bacteremia. Clin Infect Dis 46: 193-200. 807 
Spindler EC, Hale JD, Giddings TH, Jr., Hancock RE & Gill RT (2011) Deciphering the 808 
mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob Agents 809 
Chemother 55: 1706-1716. 810 
Stromstedt AA, Pasupuleti M, Schmidtchen A & Malmsten M (2009) Evaluation of 811 
strategies for improving proteolytic resistance of antimicrobial peptides by using variants 812 
of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother 53: 593-602. 813 
Sun F, Cho H, Jeong DW, Li C, He C & Bae T (2011) Aureusimines in Staphylococcus 814 
aureus are not involved in virulence. PLoS One 5: e15703. 815 
Suree N, Yi SW, Thieu W, et al. (2009) Discovery and structure-activity relationship 816 
analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem 17: 7174-817 
7185. 818 
Szynol A, de Haard JJ, Veerman EC, de Soet JJ & van Nieuw Amerongen AV (2006) 819 
Design of a peptibody consisting of the antimicrobial peptide dhvar5 and a llama variable 820 
heavy-chain antibody fragment. Chem Biol Drug Des 67: 425-431. 821 
Tew GN, Clements D, Tang H, Arnt L & Scott RW (2006) Antimicrobial activity of an 822 
abiotic host defense peptide mimic. Biochim Biophys Acta 1758: 1387-1392. 823 
Tomasinsig L, Morgera F, Antcheva N, Pacor S, Skerlavaj B, Zanetti M & Tossi A 824 
(2009) Structure dependence of biological activities for primate cathelicidins. J Pept Sci 825 
15: 576-582. 826 
Turner-Brannen E, Choi KY, Lippert DN, Cortens JP, Hancock RE, El-Gabalawy H & 827 
Mookherjee N (2011) Modulation of interleukin-1beta-induced inflammatory responses 828 
39 
 
by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial 829 
fibroblasts. Arthritis Res Ther 13: R129. 830 
Voyich JM, Braughton KR, Sturdevant DE, et al. (2005) Insights into mechanisms used 831 
by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 175: 832 
3907-3919. 833 
Weiss WJ, Lenoy E, Murphy T, et al. (2004) Effect of srtA and srtB gene expression on 834 
the virulence of Staphylococcus aureus in animal models of infection. J Antimicrob 835 
Chemother 53: 480-486. 836 
Westerhoff HV, Juretić D, Hendler RW & Zasloff M (1989) Magainins and the 837 
disruption of membrane-linked free-energy transduction. Proc Natl Acad Sci U S A 86: 838 
6597-6601. 839 
Wright JS, 3rd, Jin R & Novick RP (2005) Transient interference with staphylococcal 840 
quorum sensing blocks abscess formation. Proc Natl Acad Sci U S A 102: 1691-1696. 841 
Wyatt MA, Wang W, Roux CM, Beasley FC, Heinrichs DE, Dunman PM & Magarvey 842 
NA Staphylococcus aureus nonribosomal peptide secondary metabolites regulate 843 
virulence. Science 329: 294-296. 844 
Yang D & Oppenheim JJ (2004) Multiple functions of antimicrobial peptides in host 845 
immunity. Mammalian Host Defence Peptides,(Hancock REW & Devine D, ed.^eds.), 846 
p.^pp. Cambridge Univ. Press, New York, AMCM, Series. 847 
Yeaman MR, Bayer AS, Koo SP, Foss W & Sullam PM (1998) Platelet microbicidal 848 
proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic 849 
membrane by distinct mechanisms of action. J Clin Invest 101: 178-187. 850 
Yeung AT, Gellatly SL & Hancock RE (2011) Multifunctional cationic host defence 851 
peptides and their clinical applications. Cell Mol Life Sci 68: 2161-2176. 852 
Yoon EJ, Kwon AR, Min YH & Choi EC (2008) Foggy D-shaped zone of inhibition in 853 
Staphylococcus aureus owing to a dual character of both inducible and constitutive 854 
resistance to macrolide-lincosamide-streptogramin B. J Antimicrob Chemother 61: 533-855 
540. 856 
40 
 
Zhanel GG, Lam A, Schweizer F, et al. (2008) Ceftobiprole: A Review of a Broad-857 
Spectrum and Anti-MRSA Cephalosporin. Am J Clin Dermatol. 9: 245-254. 858 
Zhanel GG, Calic D, Schweizer F, et al. (2010) New lipoglycopeptides: a comparative 859 
review of dalbavancin, oritavancin and telavancin. Drugs 70: 859-886. 860 
Zhang L & Falla TJ (2006) Antimicrobial peptides: therapeutic potential. Expert Opin 861 
Pharmacother 7: 653-663. 862 
Zhao Z, Ma Y, Dai C, et al. (2009) Imcroporin, a new cationic antimicrobial peptide from 863 
the venom of the scorpion Isometrus maculates. Antimicrob Agents Chemother 53: 3472-864 
3477. 865 
 866 
 867 
868 
41 
 
 869 
 870 
871 
42 
 
 872 
Figure Legends 873 
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Figure 1. New MRSA agents in clinical use (*) and MRSA agents in development  877 
 878 
 879 
 880 
Figure 2. Dual effects of host defence peptides  881 
 882 
Host defence peptides can exert anti-bacterial effects directly by forming pores in the cell 883 
membrane or can modulate the immune response to infection by inducing transcription of 884 
cytokines or directing cellular components of the immune system such as neutrophils, 885 
dendritic cells, monocytes and macrophages  to the site of infection.  886 
 887 
 888 
Figure  3. Mechanism of sortase processing of MSCRAAMS.  Sortase B cleaves at the 889 
LPXTG motif to allow display of MSCRAAMS at cell surface.  Their display facilitates 890 
adhesion to host cells. If sortase is inhibited, the bacterial cell has reduced adhesion to the 891 
host cell as the surface adhesins are not displayed.  892 
 893 
